Clinical Cancer Research The Science of Cancer Health Disparities Infection and Cancer: Biology, Therapeutics, and Prevention
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nimmanapalli, R.
Right arrow Articles by Bhalla, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nimmanapalli, R.
Right arrow Articles by Bhalla, K.
Clinical Cancer Research Vol. 7, 350-357, February 2001
© 2001 American Association for Cancer Research

Experimental Therapeutics, Preclinical Pharmacology

Cotreatment with STI-571 Enhances Tumor Necrosis Factor {alpha}-related Apoptosis-inducing Ligand (TRAIL or Apo-2L)- induced Apoptosis of Bcr-Abl-positive Human Acute Leukemia Cells

Ramadevi Nimmanapalli, Mercedes Porosnicu, Diep Nguyen, Elizabeth Worthington, Erica O’Bryan, Charles Perkins and Kapil Bhalla1

Interdisciplinary Oncology Program, Moffitt Cancer Center, University of South Florida, Tampa, Florida 33612 [R. N., E. O., K. B.], and Sylvester Comprehensive Cancer Center, University of Miami School of Medicine, Miami, Florida 33136 [M. P., D. N., E. W., C. P.]

Bcr-Abl tyrosine kinase inhibitor STI-571 induces differentiation and apoptosis of HL-60/Bcr-Abl (with ectopic expression of p190 Bcr-Abl) and K562 (with endogenous expression of p210 Bcr-Abl) cells (Blood, 96: 2246–2253, 2000). Cotreatment with STI-571 partially overcomes the resistance to antileukemic drug-induced apoptosis of HL-60/Bcr-Abl and K562 cells. Tumor necrosis factor (TNF) {alpha}related apoptosis-inducing ligand (Apo-2L/TRAIL), after binding with its signaling death receptors (DR4 and DR5), triggers the intrinsic "mitochondrial" pathway of apoptosis more efficiently in the cancer than do normal cells. In the present studies, we compared the apoptotic effects of Apo-2L/TRAIL, with or without cotreatment with STI-571, in HL-60/neo, HL-60/Bcr-Abl, and K562 cells. As compared with HL-60/neo, HL-60/Bcr-Abl and K562 cells are relatively resistant to Apo-2L/TRAIL-induced apoptosis. In HL-60/Bcr-Abl and K562 versus HL-60/neo cells, Apo-2L/TRAIL caused less cytosolic accumulation of cytochrome c and the processing of caspase-9 and -3. This was also associated with decreased processing of caspase-8, c-FLIPL and Bid. Reduced effects of Apo-2L/TRAIL in Bcr-Abl-positive leukemic cells were not attributable to diminished expression of DR4 and DR5, or higher expressions of the decoy receptors DcR1 and -2 or c-FLIPL. Cotreatment with STI-571 significantly enhanced Apo-2L/TRAIL-induced apoptosis (P < 0.01) as well as increased the processing of caspase-9 and -3 and XIAP, without affecting the levels of DR4, DR5, decoy receptors, or c-FLIPL. Cotreatment with STI-571 did not enhance Apo-2L/TRAIL-induced apoptosis of HL-60/neo cells. These studies suggest that a combined treatment with STI-571 may be an effective strategy to selectively sensitize Bcr-Abl-positive leukemic blasts to Apo-2L/TRAIL-induced apoptosis.




This article has been cited by other articles:


Home page
 Cancer Res.Home page
R. C. Briggs, K. E. Shults, L. A. Flye, S. A. McClintock-Treep, M. H. Jagasia, S. A. Goodman, F. I. Boulos, J. W. Jacobberger, G. T. Stelzer, and D. R. Head
Dysregulated Human Myeloid Nuclear Differentiation Antigen Expression in Myelodysplastic Syndromes: Evidence for a Role in Apoptosis.
Cancer Res., May 1, 2006; 66(9): 4645 - 4651.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Z. Wang, J. Sampath, S. Fukuda, and L. M. Pelus
Disruption of the Inhibitor of Apoptosis Protein Survivin Sensitizes Bcr-abl-Positive Cells to STI571-Induced Apoptosis
Cancer Res., September 15, 2005; 65(18): 8224 - 8232.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
F. Guo, C. Sigua, P. Bali, P. George, W. Fiskus, A. Scuto, S. Annavarapu, A. Mouttaki, G. Sondarva, S. Wei, et al.
Mechanistic role of heat shock protein 70 in Bcr-Abl-mediated resistance to apoptosis in human acute leukemia cells
Blood, February 1, 2005; 105(3): 1246 - 1255.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
T. O'Hare, R. Pollock, E. P. Stoffregen, J. A. Keats, O. M. Abdullah, E. M. Moseson, V. M. Rivera, H. Tang, C. A. Metcalf III, R. S. Bohacek, et al.
Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML
Blood, October 15, 2004; 104(8): 2532 - 2539.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
C. Tecchio, V. Huber, P. Scapini, F. Calzetti, D. Margotto, G. Todeschini, L. Pilla, G. Martinelli, G. Pizzolo, L. Rivoltini, et al.
IFN{alpha}-stimulated neutrophils and monocytes release a soluble form of TNF-related apoptosis-inducing ligand (TRAIL/Apo-2 ligand) displaying apoptotic activity on leukemic cells
Blood, May 15, 2004; 103(10): 3837 - 3844.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
S. O'Brien, A. Tefferi, and P. Valent
Chronic Myelogenous Leukemia and Myeloproliferative Disease
Hematology, January 1, 2004; 2004(1): 146 - 162.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Younes and M. E. Kadin
Emerging Applications of the Tumor Necrosis Factor Family of Ligands and Receptors in Cancer Therapy
J. Clin. Oncol., September 15, 2003; 21(18): 3526 - 3534.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
T. R. Singh, S. Shankar, X. Chen, M. Asim, and R. K. Srivastava
Synergistic Interactions of Chemotherapeutic Drugs and Tumor Necrosis Factor-related Apoptosis-inducing Ligand/Apo-2 Ligand on Apoptosis and on Regression of Breast Carcinoma in Vivo
Cancer Res., September 1, 2003; 63(17): 5390 - 5400.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
B. Zheng, P. Fiumara, Y. V. Li, G. Georgakis, V. Snell, M. Younes, J. N. Vauthey, A. Carbone, and A. Younes
MEK/ERK pathway is aberrantly active in Hodgkin disease: a signaling pathway shared by CD30, CD40, and RANK that regulates cell proliferation and survival
Blood, August 1, 2003; 102(3): 1019 - 1027.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
S. Ghaffari, Z. Jagani, C. Kitidis, H. F. Lodish, and R. Khosravi-Far
Cytokines and BCR-ABL mediate suppression of TRAIL-induced apoptosis through inhibition of forkhead FOXO3a transcription factor
PNAS, May 27, 2003; 100(11): 6523 - 6528.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. Yu, M. Rahmani, J. Almenara, M. Subler, G. Krystal, D. Conrad, L. Varticovski, P. Dent, and S. Grant
Histone Deacetylase Inhibitors Promote STI571-mediated Apoptosis in STI571-sensitive and -resistant Bcr/Abl+ Human Myeloid Leukemia Cells
Cancer Res., May 1, 2003; 63(9): 2118 - 2126.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
V. Hietakangas, M. Poukkula, K. M. Heiskanen, J. T. Karvinen, L. Sistonen, and J. E. Eriksson
Erythroid Differentiation Sensitizes K562 Leukemia Cells to TRAIL-Induced Apoptosis by Downregulation of c-FLIP
Mol. Cell. Biol., February 15, 2003; 23(4): 1278 - 1291.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
Z.-y. Wang
Ham-Wasserman Lecture: Treatment of Acute Leukemia by Inducing Differentiation and Apoptosis
Hematology, January 1, 2003; 2003(1): 1 - 13.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. Nimmanapalli, E. O'Bryan, M. Huang, P. Bali, P. K. Burnette, T. Loughran, J. Tepperberg, R. Jove, and K. Bhalla
Molecular Characterization and Sensitivity of STI-571 (Imatinib Mesylate, Gleevec)-resistant, Bcr-Abl-positive, Human Acute Leukemia Cells to SRC Kinase Inhibitor PD180970 and 17-Allylamino-17-demethoxygeldanamycin
Cancer Res., October 15, 2002; 62(20): 5761 - 5769.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. G. Ferreira, M. Epping, F. A. E. Kruyt, and G. Giaccone
Apoptosis: Target of Cancer Therapy
Clin. Cancer Res., July 1, 2002; 8(7): 2024 - 2034.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
F. Guo, R. Nimmanapalli, S. Paranawithana, S. Wittman, D. Griffin, P. Bali, E. O'Bryan, C. Fumero, H. G. Wang, and K. Bhalla
Ectopic overexpression of second mitochondria-derived activator of caspases (Smac/DIABLO) or cotreatment with N-terminus of Smac/DIABLO peptide potentiates epothilone B derivative-(BMS 247550) and Apo-2L/TRAIL-induced apoptosis
Blood, May 1, 2002; 99(9): 3419 - 3426.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. Yu, G. Krystal, L. Varticovksi, R. McKinstry, M. Rahmani, P. Dent, and S. Grant
Pharmacologic Mitogen-activated Protein/Extracellular Signal-regulated Kinase Kinase/Mitogen-activated Protein Kinase Inhibitors Interact Synergistically with STI571 to Induce Apoptosis in Bcr/Abl-expressing Human Leukemia Cells
Cancer Res., January 1, 2002; 62(1): 188 - 199.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
B. J. Druker, S. G. O'Brien, J. Cortes, and J. Radich
Chronic Myelogenous Leukemia
Hematology, January 1, 2002; 2002(1): 111 - 135.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2001 by the American Association for Cancer Research.